Aetram Research India: NIFTY PHARMA Weekly Sector Outlook
Nifty Pharma’s Earlier Advance Pauses Near 26,500; Reclaiming 26,635 Could Restore Strength, While Losing 26,500 Risks 26,300 - 12.09.2026
Current Market Price: 26,532.40
Market Prediction:
- Nifty Pharma’s earlier upward trend has given way to consolidation near its moving averages. The latest dip places the index below that cluster, while RSI near 46 signals mild weakness rather than an exhausted decline. Regaining 26,635 could revive interest toward 26,800; a sustained move below 26,500 would threaten 26,300.
Upcoming Events:
- Positive catalyst: Softer August wholesale inflation on 14 September could ease pharmaceutical manufacturing cost concerns.
- Positive catalyst: Stronger employment signals in the August PLFS bulletin, scheduled for 15 September, could support domestic market sentiment.
- Negative catalyst: A restrictive Federal Reserve decision on 16 September could weigh on global equity sentiment.
Major Support and Resistance:
- Support: 26,500, 26,300, 26,000
- Resistance: 26,635, 26,800, 27,000
Volume Analysis:
- Nifty Pharma’s recent sideways movement has generally occurred on subdued volume, despite occasional isolated spikes. The latest dip does not show exceptional selling activity; equally, buying participation is insufficient to confirm renewed upward momentum.
Final Take Away:
- Nifty Pharma retains more of its earlier advance than several other sectors reviewed, but its immediate position has weakened. The response at 26,500 matters most; strength above 26,635 would improve the near-term picture.
Next Week Prediction:
- Nifty Pharma may remain range-bound while 26,500 holds and 26,635 caps recovery. Losing support could invite 26,300; clearing resistance would bring 26,800 into view.
Scenario-Based Outlook:
- Bullish Scenario: Above 26,635, price may move toward the 26,800–27,000 zone.
- Bearish Scenario: Below 26,500, downside risk increases toward the 26,300–26,000 zone.
- Neutral Scenario: Between 26,500–26,635, consolidation is likely.
Disclaimer: This research report is for informational purposes only. This is not an offer to buy or sell securities. Past performance is not indicative of future results. There is no guarantee of returns. Investments in securities are subject to market risks including loss of capital. Investors should consult their financial advisor before making any investment decisions.
